Cancer biotherapy最新文献_第8页

Thymidine kinases: the enzymes and their clinical usefulness. 胸苷激酶:酶及其临床应用。

Cancer biotherapy Pub Date : 1993-01-01 DOI: 10.1089/cbr.1993.8.189

B M Hannigan, Y A Barnett, D B Armstrong, V J McKelvey-Martin, P G McKenna

{"title":"Thymidine kinases: the enzymes and their clinical usefulness.","authors":"B M Hannigan, Y A Barnett, D B Armstrong, V J McKelvey-Martin, P G McKenna","doi":"10.1089/cbr.1993.8.189","DOIUrl":"https://doi.org/10.1089/cbr.1993.8.189","url":null,"abstract":"Thymidine kinases (TK) convert thymidine, or deoxythymidine (dT) to the respective monophosphate. TK occurs in many different procaryotic and eucaryotic species and different TK isoenzymes are found within the same eucaryotic cell. One isoenzyme (foetal, cytoplasmic, TK1) is associated with cell division while the other (adult, mitochondrial, TK2) is cell cycle independent. The relative isoenzyme activities in a tissue thus reflect the fraction of proliferating cells. The gene encoding TK1 has been cloned for many species and regulation of its expression is known to be complex. Increases in TK activity appear to correlate with the presence of human neoplasia and disease progression and regression have been reported to correlate with TK levels in many cancer types. TK estimations in human lymphoproliferative diseases have implicated this enzyme as an early marker of maldifferentiation. TK levels may also be increased in non-dividing mammalian cells infected with RNA or DNA viruses. Some virus encoded TK has been shown to differ biochemically, immunologically and in substrate specificity from the corresponding TK isoenzymes in target host cells thus facilitating the development of specific antiviral therapeutics. Further, TK1 in leukemic cells may differ biochemically from normal cellular TK1 such that tumor-specific TK may provide a target for tumor detection and therapy. TK quantitation has conventionally been performed in assays of enzyme activity using radiolabeled (3H or 125I) nucleoside substrates. The development of TK1-specific, non-radioisotope based immunoassays and the measurement of TK mRNA in tumour tissue using TK (DNA or RNA) probes may prove sufficiently valuable to be incorporated into the routine clinical management of human cancer.","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"8 3","pages":"189-97"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1993.8.189","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18803286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 50

Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2: a pilot study. 膀胱内白细胞介素-2治疗膀胱移行细胞癌的初步研究。

Cancer biotherapy Pub Date : 1993-01-01 DOI: 10.1089/cbr.1993.8.223

L G Gomella, D E McGinnis, E C Lattime, K Butler, M Baltish, I Thompson, M E Marshall

{"title":"Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2: a pilot study.","authors":"L G Gomella, D E McGinnis, E C Lattime, K Butler, M Baltish, I Thompson, M E Marshall","doi":"10.1089/cbr.1993.8.223","DOIUrl":"https://doi.org/10.1089/cbr.1993.8.223","url":null,"abstract":"Human recombinant interleukin-2 (rIL-2) administered systemically can mediate the regression of solid tumors in some patients. IL-2 has been detected in the bladder effluent from patients treated with intravesical BCG for transitional cell carcinoma of the bladder (TCC), suggesting that IL-2 may be an effector molecule in the mechanism of action of BCG. The purpose of the pilot study was to determine the response rate, duration of response and toxicity of rIL-2 (Cetus) administered intravesically to previously untreated patients and patients who had failed prior intravesical therapy with other agents. Fourteen patients with biopsy proven transitional cell carcinoma (13 Stage TIS/Ta/T1, 1 Stage T2) were treated with 8 weekly instillations of 12 x 10(6) IU of rIL-2. An index lesion was followed with cystoscopy, biopsy and cytology at three months, with identical follow up every three months thereafter if a response was noted in the index lesion at the first evaluation. There were 3 complete responses (duration of response measured from start of treatment to date of progression) of 9+, 3, 9 months; one patient with TIS, and 2 patients with Ta disease. There were 11 non-responders for an overall response rate of 21%. One patient with extensive CIS had a dramatic partial response and was converted to a complete response with a second 8-week course of rIL-2. All of the complete responders had failed prior intravesical therapy with standard agents. Toxicity from rIL-2 given intravesically was minimal. One patient reported malaise for 24 hours after each treatment and two patients developed asymptomatic lower UTIs.(ABSTRACT TRUNCATED AT 250 WORDS)","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"8 3","pages":"223-7"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1993.8.223","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18803288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Limited efficacy of interferon-alpha and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinoma. 干扰素- α和长春碱作为进展性转移性肾细胞癌患者的二线生物化疗方案的有限疗效。

Cancer biotherapy Pub Date : 1993-01-01 DOI: 10.1089/cbr.1993.8.301

E Lopez Hanninen, M Fenner, H Kirchner, M Deckert, S Duensing, T Menzel, H Poliwoda, J Atzpodien

{"title":"Limited efficacy of interferon-alpha and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinoma.","authors":"E Lopez Hanninen, M Fenner, H Kirchner, M Deckert, S Duensing, T Menzel, H Poliwoda, J Atzpodien","doi":"10.1089/cbr.1993.8.301","DOIUrl":"https://doi.org/10.1089/cbr.1993.8.301","url":null,"abstract":"We report on thirty-four patients with metastatic renal cell carcinoma who were treated with a combination of subcutaneous recombinant interferon-alpha and intravenous vinblastine upon progression after previous antineoplastic therapy. Pretreatment included chemotherapy (n = 3), hormonal therapy (n = 6) and immunotherapy (interleukin-2/interferon-alpha, n = 25). In this study, treatment courses consisted of subcutaneous doses thrice weekly of recombinant interferon-alpha at 6 million U/m2 (20 patients, group 2), respectively. Treatment was given over 8 consecutive weeks. Additionally, in all patients, vinblastine was administered intravenously at a dose of 6 mg/m2 in weeks 2, 5 and 8. Of 14 patients treated in group 1, one had a partial response for 6 months (overall response rate 7.14%; 95% confidence interval, 0.18-33.87%), and four had disease stabilization (median duration, 5.0 months). Of 20 patients treated in group 2, there was one patient who achieved a complete response (response duration, 34+ months); in addition, two patients had a partial response (median response duration, 10.5+ months; overall response rate, 15%; 95% confidence interval 3.21-37.89%), and 13 patients exhibited disease stabilization (median duration 5.9+ months). Response rates showed no significant differences when comparing treatment results in patients in group 1 vs group 2. In contrast, significantly less patients treated in group 2 had progressive disease (p = 0.024), as compared to patients in group 1. This treatment combination was overall well tolerated with low to moderate systemic toxicity. In addition, there were no significant differences in frequency or intensity of therapy-related systemic toxicities when comparing patients in group 1 and group 2, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"8 4","pages":"301-6"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1993.8.301","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18803809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Recombinant bifunctional molecule FV/IFN-gamma possesses the anti-tumor FV as well as the gamma interferon activities. 重组双功能分子FV/ ifn - γ具有抗肿瘤FV和γ干扰素活性。

Cancer biotherapy Pub Date : 1993-01-01 DOI: 10.1089/cbr.1993.8.327

J Xiang, Y Qi, X Luo, E Liu

引用次数: 9

c-erbB-2 DNA amplification and mRNA expression in human primary breast tumors and its relationship to other prognostic factors. 人原发性乳腺肿瘤c-erbB-2 DNA扩增和mRNA表达及其与其他预后因素的关系

Cancer biotherapy Pub Date : 1993-01-01 DOI: 10.1089/cbr.1993.8.29

M A Nagai, M M Pacheco, C T Oshima, M M Brentani

引用次数: 7

High binding affinity chimeric anti-colorectal carcinoma antibody correlated to enhanced tumor binding and effector function. 高结合亲和嵌合抗结直肠癌抗体与增强肿瘤结合和效应功能相关。

Cancer biotherapy Pub Date : 1993-01-01 DOI: 10.1089/cbr.1993.8.171

J Xiang, T Moyana, Z Chen, L Skinnider, T Hamilton, D Sun

引用次数: 2

Increased oxygen tensions modulate the cellular composition of the adaptive immune system in BALB/c mice. 增加的氧张力调节BALB/c小鼠适应性免疫系统的细胞组成。

Cancer biotherapy Pub Date : 1993-01-01 DOI: 10.1089/cbr.1993.8.241

A K Lee, R B Hester, J H Coggin, S F Gottlieb

引用次数: 3

Cancer biotherapy: 1993 to the millenium and more! 癌症生物治疗:1993年到千禧年以上!

Cancer biotherapy Pub Date : 1993-01-01 DOI: 10.1089/cbr.1993.8.1

R K Oldham

引用次数: 2

A pilot clinical and pharmacological study of intra-arterial infusion of thiotepa. 动脉输注硫替帕的初步临床和药理研究。

Cancer biotherapy Pub Date : 1993-01-01 DOI: 10.1089/cbr.1993.8.37

N Savaraj, L G Feun, G Blyden, J M Yrizarry, J T Hsiang, J Curtas, S Waldman, J D Post, P Benedetto, H Landy

引用次数: 0

Evaluation of a new test for colorectal neoplasms: a prospective study of asymptomatic population. 评估结直肠肿瘤的新测试:一项对无症状人群的前瞻性研究。

Cancer biotherapy Pub Date : 1993-01-01 DOI: 10.1089/cbr.1993.8.49

K Sakamoto, M Muratani, T Ogawa, Y Nagamachi

{"title":"Evaluation of a new test for colorectal neoplasms: a prospective study of asymptomatic population.","authors":"K Sakamoto, M Muratani, T Ogawa, Y Nagamachi","doi":"10.1089/cbr.1993.8.49","DOIUrl":"https://doi.org/10.1089/cbr.1993.8.49","url":null,"abstract":"In a recent pilot study, we have suggested of potential usefulness of a new test (Shams' test) for screening colorectal (CR) cancer in Japan. Although the sensitivity of this test was remarkably high, its accurate specificity was unclear. The purpose of our present study is to evaluate the incidence of non-specific reaction of Shams' test in the normal Japanese populations. We analyzed 330 asymptomatic individuals, who were seen for annual health checkup, for the presence of the tumor marker D-Gal-B (1- > 3)-D-GalNAc in their rectal mucin. The rectal mucin was smeared on nitrocellulose membrane filter and developed by a sequential reaction of B-D-galactose oxidase and Schiff's reagent. Immunological fecal occult blood test (FOBT) was done in parallel. Extensive study by barium enema/total colonoscopy was indicated only for those who showed positive results with Shams' test or FOBT. A total of 271 individuals were negative, while 50 and 9 had positive and equivocal (+/-) results, respectively. Subsequent barium enema and fiberoptic proctocolonoscopic examinations, which were available on 32 of 59 cases, revealed 6 adenomatous polyps, one villous adenoma with focal severe atypia, and 4 cases of diverticular disease. Except for one patient with polyp, 6 other patients harboring polyps were negative with immunological FOBT. The overall specificity of Shams' test was 92.2% (271/294). Based on these results and preceding reports, we concluded that Shams' test could be a useful tool in our strategy for early detection of CR neoplasms and precancerous lesions.","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"8 1","pages":"49-55"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1993.8.49","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18812889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12